Novocure Ltd - Asset Resilience Ratio
Novocure Ltd (NVCR) has an Asset Resilience Ratio of 43.72% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Novocure Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Novocure Ltd's Asset Resilience Ratio has changed over time. See NVCR net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Novocure Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Novocure Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $344.48 Million | 43.72% |
| Total Liquid Assets | $344.48 Million | 43.72% |
Asset Resilience Insights
- Very High Liquidity: Novocure Ltd maintains exceptional liquid asset reserves at 43.72% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Novocure Ltd Industry Peers by Asset Resilience Ratio
Compare Novocure Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for Novocure Ltd (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Novocure Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 44.03% | $354.13 Million | $804.33 Million | -20.13pp |
| 2024-12-31 | 64.16% | $796.11 Million | $1.24 Billion | +5.72pp |
| 2023-12-31 | 58.44% | $669.79 Million | $1.15 Billion | -13.23pp |
| 2022-12-31 | 71.67% | $854.10 Million | $1.19 Billion | +7.71pp |
| 2021-12-31 | 63.97% | $728.90 Million | $1.14 Billion | +6.18pp |
| 2020-12-31 | 57.79% | $607.90 Million | $1.05 Billion | +26.76pp |
| 2019-12-31 | 31.03% | $148.77 Million | $479.45 Million | +0.05pp |
| 2018-12-31 | 30.98% | $105.26 Million | $339.79 Million | -8.50pp |
| 2017-12-31 | 39.47% | $104.72 Million | $265.30 Million | -3.02pp |
| 2016-12-31 | 42.49% | $119.85 Million | $282.08 Million | -6.32pp |
| 2015-12-31 | 48.81% | $150.00 Million | $307.34 Million | +10.63pp |
| 2014-12-31 | 38.17% | $45.00 Million | $117.88 Million | +37.55pp |
| 2013-12-31 | 0.62% | $1.18 Million | $188.91 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more